Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177 Lu-PSMA and Combined 225 Ac- and 177 Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: : A Single-Center Systematic Investigation

Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xerostomia and becomes dose-limiting for 225 Ac-PSMA-617. This study investigated the sialotoxicity of 177 Lu-PSMA-I&T/-617 monotherapy and co-administered 225 Ac-PSMA-617 and 177 Lu-PSMA-617 (Tandem-PPRLT). Methods: Three patient cohorts, that had undergone 177 Lu-PSMA-I&T/-617 monotherapy or Tandem-PRLT, were retrospectively analyzed. In a short-term cohort (91 patients), a xerostomia assessment (CTCAE v.5.0), a standardized questionnaire (sXI), salivary gland scintigraphy (SGS), and SG SUVmax and the metabolic volume (MV) on 68 Ga-PSMA-11-PET/CT were obtained before and after two cycles of 177 Lu-PSMA-I&T/-617. In a long-term cohort, 40 patients were similarly examined. In a Tandem cohort, the same protocol was applied to 18 patients after one cycle of Tandem-PRLT. Results: Grade 1 xerostomia in the short-term follow-up was observed in 22 (24.2%) patients with a worsening of sXI from 7 to 8 at ( p < 0.05). In the long-term cohort, xerostomia grades 1 to 2 occurred in 16 (40%) patients. SGS showed no significant changes, but there was a decline of the MV of all SGs. After Tandem-PRLT, 12/18 (66.7%) patients reported xerostomia grades 1 to 2, and the sXI significantly worsened from 9.5 to 14.0 ( p = 0.005), with a significant reduction in the excretion fraction (EF) and MV of all SGs. Conclusion: 177 Lu-PSMA-I&T/-617 causes only minor SG toxicity, while one cycle of Tandem-PRLT results in a significant SG impairment. This standardized protocol may help to objectify and quantify SG dysfunction.